Efficacy and outcome of autologous transplantation in rare myelomas

Haematologica

Volumn 95, Issue 12, 2010, Pages 2126-2133

  Morris, Curly ^a   Drake, Mary ^a   Apperley, Jane ^b   Iacobelli, Simona ^c   van Biezen, Anja ^d   Bjorkstrand, Bo ^e   Goldschmidt, Hartmut ^f   Harousseau, Jean Luc ^g   Morgan, Gareth ^h   de Witte, Theo ⁱ   Niederwieser, Dietger ^j   Gahrton, Gosta ^e  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g HÔTEL DIEU   (France)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^j UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

Autologous transplantation; Efficacy; Outcome; Rare myelomas

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M;

ADULT; ADVERSE OUTCOME; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN A MYELOMA; IMMUNOGLOBULIN D MYELOMA; IMMUNOGLOBULIN E MYELOMA; IMMUNOGLOBULIN G MYELOMA; IMMUNOGLOBULIN M MYELOMA; LIGHT CHAIN MYELOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELOMA; NON SECRETORY MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 78649820146     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.022848     Document Type: Article

References (32)

1. Kyle RA, Gertz MA, Witzig TE, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
2. Fibbe WE, Jansen J. Prognostic factors in IgD myeloma: a study of 21 cases. Scand J Haematol. 1984;33(5):471-5.
3. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med. 1975;135(1):87-93.
4. Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol. 1991;47(4):262-7.
5. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12(11):2398-404.
6. Cavo M, Galieni P. Gobbi M, Baldrati L, Leardini L, Baccarani M, et al. Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. Acta Haematol. 1985;74(1):27-30.
7. Rubio-Felix D, Giralt M, Giraldo MP, Martinez-Peñuela JM, Oyarzabal F, Sala F, et al. Nonsecretory multiple myeloma. Cancer. 1987;59(10):1847-52.
8. Bourantas K. Nonsecretory multiple myeloma. Eur J Haematol. 1996;56(1-2):109-11.
9. Dreicer R, Alexanian R. Nonsecretory multiple myeloma. Am J Hematol. 1982;13(4): 313-8.
10. Smith DB, Harris M, Gowland E, Chang J, Scarffe JH. Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol. 1986;4(4): 307-13.
11. Drake MB, Iacobelli S, van Biezen A, Apperley J, Niederwieser D, Bjorkstrand B, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95(5):804-9.
12. Björkstrand B, Gahrton G. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future. Semin Hematol. 2007;44(4): 227-33.
13. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant. 2009;43(4):275-91.
14. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93(1):55-65.
15. Attal M, Harousseau J L, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91-7.
16. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stemcell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-83.
17. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13(6):1259-72.
18. Nair B, Waheed S, Szymonifka J, Shaughnessy JD Jr, Crowley J, Barlogie B. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. Br J Haematol. 2009;145(1):134-7.
19. Kettle P, Morris TC. Late relapse in IgD myeloma: value of immunohistochemistry in trephine biopsy specimens. J Clin Pathol. 1994;47(8):773-4.
20. Zitouni M, Barbouche MR, Ayed K, Makni S. Clinical features, autoantibody activity, and survival in nine Tunisian patients with IgD myeloma. Rev Rhum Eng Ed. 1999;66 (2):122.
21. Bemelmans RH, van Toorn DW, van Leeuwen L, Schaar CG. Long-term complete remission in IgD-myeloma. Eur J Haematol. 2006;76(4):339-41.
22. Hayes MJ, Carey JL, Krauss JC, Hedstrom DL, Gulbranson RL, Keren DF. Low IgE monoclonal gammopathy level in serum highlights 20-yr survival in a case of IgE muliple myeloma. Eur J Haematol. 2007;78 (4):353-7.
23. Morris TCM, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D, et al. Benefit and timing of second transplantations in multiple myeloma; clinical findings and methodological limitations in an EBMT registry study. J Clin Oncol. 2004;22(9): 1674-81.
24. Kumar S, Pérez WS, Zhang MJ, Ballen K, Bashey A, To LB, et al. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(10):1134-40.
25. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant. 2003;31(3):163-70.
26. Morris TCM, Velangi M, Jackson G, Marks DI, et al. Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population based survey. Br J Haematol. 2005;128(4):510-2.
27. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R; Intergroupe Francophone du Myélome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570-1.
28. Feyler S, O'Connor SJ, Rawstron AC, Subash C, Ross FM, Pratt G, et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol. 2008;140 (5):547-51.
29. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4): 673-80.
30. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215-24.
31. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-8.
32. Annibali O, Petrucci MT, Del Bianco P, Gallucci C, Levi A, Foà R, et al. IgM multiple myeloma: report of four cases and review of the literature. Leuk Lymphoma. 2006;47(8): 1565-9.